Allspring Global Investments
NGNE icon

Allspring Global Investments’s Neurogene NGNE Stock Holding History

Allspring Global Investments’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,285
Closed -$85K – 2843
2022
Q1 		$85K Buy
+2,285
New +$133K ﹤0.01% 2778

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Allspring Global Investments's NGNE Position: Q2 2022 in Review

Allspring Global Investments sold out of Neurogene (NGNE) in Q2 2022, closing a stake of 2,285 shares — an estimated $85K sold.

Allspring Global Investments first reported a position in NGNE in Q1 2022 and held it in 1 quarter. The position peaked at $85K in Q1 2022. 63 funds tracked by Wall St. Rank hold NGNE as of Q2 2022.

  • Allspring Global Investments reported no remaining Neurogene position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 2,285 Neurogene shares in Q2 2022, an estimated $85K.
  • Allspring Global Investments first reported a position in Neurogene in Q1 2022 and held it in 1 quarter.
  • Allspring Global Investments's Neurogene position peaked at $85K in Q1 2022.
  • 63 funds tracked by Wall St. Rank held Neurogene as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.